publication date: Mar. 11, 2016

Esener to Lead Early Detection Research At OHSU Knight Cancer Institute 

 

SADIK ESENER will direct the Center for Early Detection Research at Oregon Health and Science University’s Knight Cancer Institute. Esener will also hold the Wendt Family Endowed Chair in Early Cancer Detection.

Esener is a professor of nanoengineering and electrical and computer engineering at the Jacobs School of Engineering at the University of California San Diego. He has served as director and principal investigator of several centers of excellence in the areas of photonics and cancer nanotechnologies.

Most recently, he led the Cancer Nanotechnology Center of Excellence at UCSD’s Moores Cancer Center to explore ways to use nanoscale devices to detect and target cancerous tumors.

Esener’s recruitment comes just months after OHSU’s successful completion of the $1 billion Knight Cancer Challenge from Nike co-founder Phil Knight and his wife, Penny. Among Esener’s first responsibilities as director will be the recruitment of 20 to 30 scientists and their research teams to the OHSU Knight Cancer Institute’s Center for Early Detection.

A gift by the Richard L. Wendt Family and the Wendt Family Foundation ensures ongoing support for Esener’s role. It is the second such endowment created by the Wendt Family.

Esener has a breadth of experience in multiple scientific fields relevant to early cancer detection research, including micro and nanofabrication and optical, electrical and computer engineering. As a nanotechnology expert, engineer and computer scientist, he will bring an engineering systems-based approach to the role by integrating state-of-the-art technologies.

Continue reading 42-10 Esener to Lead Early Detection Research At OHSU Knight Cancer Institute

To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2020 The Cancer Letter Inc.